Borgas: Consolidation and closures required

Stefan Borgas, ceo of Lonza, believes that there is 60% overcapacity in pharmaceutical manufacturing for chemical ingredients with a highly fragmented industry. Borgas believes that some niche capabilities may offer protection, but ultimately there needs to be consolidation in the sector along with plant closures and modern, more efficient plants being built. He also warned that the biologics manufacturing sector could follow the same "sinful path" towards fragmentation and overcapacity.
In-Pharma Technologist